Reshape Lifesciences Stock Investor Sentiment

RSLS Stock  USD 0.40  0.04  9.09%   
Slightly above 71% of ReShape Lifesciences' investor base is looking to short. The analysis of overall sentiment of trading ReShape Lifesciences stock suggests that many investors are alarmed at this time. ReShape Lifesciences' investing sentiment can be driven by a variety of factors including economic data, ReShape Lifesciences' earnings reports, geopolitical events, and overall market trends.

Comfort Level 29

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use ReShape Lifesciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward ReShape Lifesciences.
74.0%
10.0%
5.0%

ReShape Historical Sentiment

Although ReShape Lifesciences' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding ReShape, such as negative comments on social media and news outlets, may cause fear in the market and push ReShape Lifesciences' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of ReShape.
  

ReShape Lifesciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ReShape Lifesciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
54.9%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ReShape Lifesciences Historical Investor Sentiment

Investor biases related to ReShape Lifesciences' public news can be used to forecast risks associated with an investment in ReShape. The trend in average sentiment can be used to explain how an investor holding ReShape can time the market purely based on public headlines and social activities around ReShape Lifesciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ReShape Lifesciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ReShape Lifesciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average ReShape Lifesciences news discussions. The higher the estimate score, the more favorable the investor's outlook on ReShape Lifesciences.
over six months ago at news.google.com         
RSLS Stock Earnings Reshape Lifesciences Misses Revenue for Q2 2024 - MSN
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over six months ago at gurufocus.com         
Reshape Lifesciences Inc Q2 2024 Earnings Call Transcript Highlights Strategic Moves ...
Gurufocus Stories at Macroaxis
over six months ago at insidermonkey.com         
ReShape Lifesciences Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over six months ago at investorplace.com         
RSLS Stock Earnings Reshape Lifesciences Misses Revenue for Q2 2024
sbwire news
over six months ago at finance.yahoo.com         
ReShape Lifesciences Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corpo...
Yahoo News
over six months ago at finance.yahoo.com         
Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.23 subject to Rule ...
Yahoo News
over six months ago at news.google.com         
ReShape Lifesciences Stock Passes Above 200 Day Moving Average of 0.19 - Defense World
Google News at Macroaxis
over six months ago at businesswire.com         
Elucid Names Kelly Huang as CEO
businesswire News
over six months ago at prnewswire.com         
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates GLXZ, RSLS, TLRS on Behalf of Shareholders
prnewswire News
over six months ago at news.google.com         
Acquisition by Thomas Stankovich of 17702 shares of ReShape Lifesciences at 1.52 subject to Rule 16b...
Google News at Macroaxis
over six months ago at businesswire.com         
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC...
businesswire News
over six months ago at businesswire.com         
RSLS Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. I...
businesswire News
over six months ago at businesswire.com         
RSLS Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. I...
businesswire News
over six months ago at news.google.com         
ReShape Lifesciences to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Pr...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about ReShape Lifesciences that are available to investors today. That information is available publicly through ReShape media outlets and privately through word of mouth or via ReShape internal channels. However, regardless of the origin, that massive amount of ReShape data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ReShape Lifesciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ReShape Lifesciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ReShape Lifesciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ReShape Lifesciences alpha.

ReShape Lifesciences Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15123456782025FebMar -80-60-40-200
JavaScript chart by amCharts 3.21.15ReShape Lifesciences ReShape Lifesciences Dividend Benchmark Dow Jones Industrial
       Timeline  
1
SHAREHOLDER NOTICE Halper Sadeh LLC Investigates LBRDA, OMIC, NEUE, RSLS on Behalf of Shareholders
01/28/2025
2
RSLS stock touches 52-week low at 2.57 amid market challenges - MSN
02/13/2025
3
Acquisition by Armistice Capital, Llc of 1479713 shares of ReShape Lifesciences at 6.0 subject to Rule 16b-3
02/18/2025
4
ReShape Lifesciences Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX
02/25/2025
5
Acquisition by Armistice Capital, Llc of tradable shares of ReShape Lifesciences subject to Rule 16b-3
03/14/2025
6
Disposition of 157 shares by Thomas Stankovich of ReShape Lifesciences at 13.29 subject to Rule 16b-3
03/18/2025
7
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
03/21/2025
8
RSLS stock touches 52-week low at 0.49 amid sharp annual decline - Investing.com India
03/26/2025

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.